Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $28.00 by Analysts at JPMorgan Chase & Co.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target reduced by investment analysts at JPMorgan Chase & Co. from $30.00 to $28.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price points to a potential upside of 54.10% from the stock's current price.

Several other equities analysts have also issued reports on SRPT. Barclays lowered their target price on shares of Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating for the company in a report on Tuesday, June 17th. BMO Capital Markets lowered shares of Sarepta Therapeutics from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $120.00 to $70.00 in a report on Monday, June 16th. UBS Group lowered their target price on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Jefferies Financial Group lowered their target price on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a "buy" rating for the company in a report on Monday, June 16th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $58.54.

Sarepta Therapeutics Trading Down 4.7%

Shares of NASDAQ:SRPT traded down $0.90 on Thursday, reaching $18.17. 3,075,372 shares of the company traded hands, compared to its average volume of 2,241,596. The business's 50-day simple moving average is $30.98 and its 200 day simple moving average is $71.91. Sarepta Therapeutics has a 52 week low of $16.88 and a 52 week high of $154.13. The stock has a market capitalization of $1.79 billion, a P/E ratio of -6.75 and a beta of 0.45. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The business's revenue for the quarter was up 80.2% on a year-over-year basis. As a group, equities analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Byrne Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics in the 1st quarter worth $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $31,000. Ancora Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after buying an additional 300 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after buying an additional 194 shares in the last quarter. Finally, Banque Transatlantique SA purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $44,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.